CA9 and acute myeloid leukemia: If CA IX and CA XII are involved in the development of AML drug resistance, then patients failing induction chemotherapy as demonstrated by an interim BM assessment routinely performed 14–21 days after the initiation of therapy should show persistent or enhanced CA IX and/or CA XII staining when compared to the diagnostic marrow.